GlassScriptPhysician profile
Gautam Jha
NPI 1447314737
$10,672.94
in general payments reported to CMS, 2019-2025
43 companies · $674 in 2025
The $674 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $3,148 · 2021: $3,388 · 2022: $802 · 2023: $909 · 2024: $923 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,486 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,486.30 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $2,044.11 | 2021 | |
| Genzyme Corporation | $1,736.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $1,298.14 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $936.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $647.61 | 2020 | |
| Lilly USA, LLC | $633.60 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $495.75 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $397.63 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $387.98 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $225.29 | 2019-2024 | |
| Pfizer INC. | $183.41 | 2019-2025 | |
| Mylan Specialty L.P. | $162.21 | 2019-2024 | Yupelri |
| Preventric Diagnostics, INC. | $151.74 | 2021 | |
| Amgen INC. | $129.95 | 2020-2024 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $127.23 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gautam Jha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.